Results 61 to 70 of about 2,979 (199)

Do Brain Extracellular Fluid Concentrations Predict PET‐Inferred Receptor Occupancy in Human CNS? A Mechanistic Model‐Based Analysis of Dopamine D2 Receptor Ligands

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1389-1401, November 2026.
A mechanistic CNS PBPK model framework was applied to eight antipsychotic D2 receptor ligands, comparing brain extracellular fluid (brainECF) and brain cell membrane (brainM) as biophase for predicting human receptor occupancy compared against PET neuroimaging data. BrainM concentrations showed improved agreement with PET‐derived receptor occupancy for
Divakar Budda, J.G. Coen van Hasselt, Elizabeth C.M. de Lange   +2 more
wiley   +1 more source

Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties:A hypothesis based on data [PDF]

, 2023
The treatment of bipolar depression is one of the most challenging needs in contemporary psychiatry. Currently, only quetiapine, olanzapine-fluoxetine combination, lurasidone, cariprazine, and recently lumateperone have been FDA-approved to treat this ...
Mauricio Tohen, Konstantinos N. Fountoulakis, Ioannou, Magdalini; id_orcid, Magdalini Ioannou, Fountoulakis, Konstantinos N., Tohen, Mauricio, Bartholomeus C.M. Haarman, Carlos A. Zarate, Zarate, Carlos A., Haarman, Bartholomeus C.M.; id_orcid   +9 more
core   +1 more source

Emotional Responses (Intensity/Valence) Fulfill RDoC Criteria but Remain Excluded From Diagnostic Classifications of Mood Disorders

Bipolar Disorders, Volume 28, Issue 7, November 2026.
ABSTRACT Objectives Categorical classifications of depression, such as DSM‐5 and ICD, are limited by high clinical heterogeneity, arbitrary diagnostic thresholds, and weak links to underlying pathophysiology. In line with the Research Domain Criteria (RDoC) framework, this article proposes a dimensional and mechanistic approach centered on emotional ...
Chantal Henry, Chlöé Müh, Claire‐Hélène de Badts, Mariana Alonso, Lucie Berkovitch   +4 more
wiley   +1 more source

A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia

Frontiers in Psychiatry
Management of negative symptoms is one of the most challenging and important unmet needs of schizophrenia treatment. Negative symptoms together with positive symptoms result in significant psychosocial impairment and poor quality of life.
Panneer Selvan, Prashant Devkare, Arthik Shetty, Shruti Dharmadhikari, Chintan Khandhedia, Amey Mane, Suyog Mehta, Chittaranjan Andrade   +7 more
doaj   +1 more source

Agomelatine as augmentation therapy with second‐generation antipsychotics for negative symptoms of schizophrenia: An open‐label randomised clinical trial and electroencephalogram‐derived model for treatment response prediction

General Psychiatry, Volume 39, Issue 5, October 2026.
ABSTRACT Background Negative symptoms are a core diagnostic domain of schizophrenia that affect functional outcomes and remain difficult to treat. Agomelatine, a novel antidepressant with melatonin receptor agonism and serotonin 2C receptor antagonism, may have therapeutic potential.
Wanyan Zhou, Fei Liang, Nizhe Chen, Yao Zhang, Xiaoxiao Wang, Xin Li, Daofeng Lu, Fang Guo, Yuan Yao, Jiayu Zhu, Chengjia Shen, Chongze Wang, Peiyun Zhang, Lilan Zhao, Ying Wang, Jinyu Han, Wei Li, Haisu Wu, Peijuan Wang, Qi Yan, Ping Zhang, Qinyu Lv, Zhenghui Yi   +22 more
wiley   +1 more source

Cariprazine as a strategy for augmentation of treatment of major depressive disorder: from pharmacological aspects to clinical practice

Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева
Major depressive disorder remains the leading cause of disability worldwide, with up to 33% of patients failing to respond to antidepressant therapy.
A. V. Kidyaeva, R. F. Nasyrova
doaj   +1 more source

Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting

Frontiers in Psychiatry, 2023
Real-world evidence fills in an important gap by providing data on the effectiveness and tolerability of new medications in everyday patients. In this data collection form a Spanish hospital, the effectiveness and tolerability of cariprazine were ...
Lluis Niell Galmes, Elmars Rancans
doaj   +1 more source

High Risk of Metabolic Side Effects Among New Paediatric Antipsychotic Users in Sweden—A Register‐Based Study

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 10, October 2026.
ABSTRACT Purpose This study aims to assess the risk of metabolic side effects among paediatric new users of antipsychotics in Sweden, focusing on differences between substances and sexes. Methods Children aged 5–17 years, who were new users of antipsychotics between 2014 and 2021, were identified using Swedish national health registers.
Elin Eyfells Kimland, Anders Sundström, Sverre Wikström, Håkan Jarbin, Elin Dahlén   +4 more
wiley   +1 more source

Volumetric Microsampling for Patient‐Centric Therapeutic Drug Monitoring in Clinical Pharmacology: A Scoping Review

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Accurate drug concentration measurement is essential for precision pharmacotherapy, but conventional therapeutic drug monitoring (TDM) requires venous sampling, increasing patient burden, and potentially limiting participation in TDM and model‐informed precision dosing (MIPD).
Hari Prabhath Tummala, Abbie D. Leino, Nathaniel J. Rhodes, Kevin J. Downes, Marc H. Scheetz, Manjunath P. Pai   +5 more
wiley   +1 more source

Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine [PDF]

, 2019
OBJECTIVE: This study examined the chronic effects of aripiprazole and cariprazine on serotonin (5-HT1A and 5-HT2A) and glutamate (NMDA and AMPA) receptor subtypes.
Adham, N, Tarazi, FI, Gyertyán, István, Choi, YK, Kiss, B   +4 more
core   +1 more source